Ping Ji Sells 5,000 Shares of Adlai Nortye (NASDAQ:ANL) Stock

Key Points

• Director Ping Ji sold 5,000 Adlai Nortye shares at an average price of $16.63, receiving $83,150. Following the transaction, Ji retained 131,667 shares, a 3.66% reduction in ownership.
• Adlai Nortye shares recently traded at $15.43, near their 52-week high of $17.25 and well above the 52-week low of $0.88. The stock’s 50-day and 200-day moving averages were $13.89 and $11.96, respectively.
• Analysts maintain a “Moderate Buy” consensus, with six Buy ratings and one Sell rating and an average price target of $29.50. Institutional investors own 35.21% of the company, with several funds establishing new positions recently.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report) Director Ping Ji sold 5,000 shares of the company's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $16.63, for a total value of $83,150.00. Following the completion of the sale, the director owned 131,667 shares of the company's stock, valued at $2,189,622.21. This trade represents a 3.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Adlai Nortye Price Performance

NASDAQ ANL traded down $0.32 on Thursday, hitting $15.43. 66,283 shares of the company traded hands, compared to its average volume of 372,919. The company has a debt-to-equity ratio of 0.04, a current ratio of 9.55 and a quick ratio of 0.65. The business's 50 day moving average price is $13.89 and its 200-day moving average price is $11.96. Adlai Nortye Ltd. Sponsored ADR has a 52-week low of $0.88 and a 52-week high of $17.25.

Analyst Ratings Changes

Several research firms recently issued reports on ANL. Wall Street Zen lowered shares of Adlai Nortye from a "buy" rating to a "hold" rating in a report on Saturday, September 12th. Oppenheimer assumed coverage on shares of Adlai Nortye in a research report on Thursday, May 28th. They issued an "outperform" rating and a $32.00 price target for the company. Loop Capital set a $49.00 price objective on shares of Adlai Nortye in a research note on Tuesday, September 8th. HC Wainwright restated a "buy" rating and set a $20.00 price objective on shares of Adlai Nortye in a research report on Tuesday, September 8th. Finally, Jefferies Financial Group started coverage on shares of Adlai Nortye in a report on Thursday, September 10th. They issued a "buy" rating and a $31.00 target price for the company. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adlai Nortye has an average rating of "Moderate Buy" and an average price target of $29.50.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Seven Fleet Capital Management LP bought a new position in Adlai Nortye during the second quarter valued at $1,302,000. Braidwell LP bought a new stake in shares of Adlai Nortye in the 2nd quarter worth about $9,145,000. Boone Capital Management LLC purchased a new stake in shares of Adlai Nortye during the 2nd quarter valued at about $2,971,000. ADAR1 Capital Management LLC purchased a new stake in shares of Adlai Nortye during the 1st quarter valued at about $816,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye in the 1st quarter valued at about $1,140,000. 35.21% of the stock is owned by hedge funds and other institutional investors.

About Adlai Nortye

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer and other serious diseases. The company's research and development activities center on oncology and immuno-oncology, with the goal of addressing unmet needs in the treatment of solid tumors.

Adlai Nortye's lead candidate is buparlisib, also known as AN2025, an oral pan-class I phosphoinositide 3-kinase (PI3K) inhibitor being developed for oncology indications, including head and neck cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.